Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clin Mol Hepatol. 2020;26(4):430-443.   Published online 2020 Aug 14     DOI: https://doi.org/10.3350/cmh.2020.0137
Citations to this article as recorded by Crossref logo
Development and prognosis of hepatocellular carcinoma in patients with diabetes
Takuma Nakatsuka, Ryosuke Tateishi
Clinical and Molecular Hepatology.2023; 29(1): 51.     CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Seung Min Lee, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(1): 171.     CrossRef
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Jihyun An, Joo Hyun Sohn
Clinical and Molecular Hepatology.2023; 29(Suppl): S268.     CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
Clinical and Molecular Hepatology.2023; 29(Suppl): S123.     CrossRef
Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection
Si Ho Kim, Eun Ju Cho, Boo‐ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong‐Hwan Yoon, Jin‐Wook Kim, Sook‐Hyang Jeong, Eun Sun Jang
Liver International.2022; 42(2): 320.     CrossRef
Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double‐blind, and placebo‐controlled study
Minyoung Lee, Woo‐je Lee, Jae Hyeon Kim, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2022; 24(6): 1105.     CrossRef
Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis
Tea Omanovic Kolaric, Tomislav Kizivat, Vjera Mihaljevic, Milorad Zjalic, Ines Bilic-Curcic, Lucija Kuna, Robert Smolic, Aleksandar Vcev, George Y. Wu, Martina Smolic
Current Issues in Molecular Biology.2022; 44(8): 3465.     CrossRef
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N
Journal of Hepatology.2022; 77(6): 1482.     CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
Hepatology Research.2022; 52(12): 975.     CrossRef
Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
Shasta Tall Bull, Wesley Nuffer, Jennifer M. Trujillo
Journal of Diabetes and its Complications.2022; 36(12): 108332.     CrossRef
Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients
Ziyin Zhang, Lu Zhang, Wangyan Jiang, Tingting Du, Gang Yuan
Cardiovascular Diabetology.2022;[Epub]     CrossRef
To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases
Wen-Ling Lee, Peng-Hui Wang, Szu-Ting Yang, Chia-Hao Liu, Wen-Hsun Chang, Fa-Kung Lee
Journal of the Chinese Medical Association.2022; 85(12): 1109.     CrossRef
Gut microbiota: The key to the treatment of metabolic syndrome in traditional Chinese medicine – a case study of diabetes and nonalcoholic fatty liver disease
Yang Bao, Xiao Han, Da Liu, Zhaolin Tan, Yongzhi Deng
Frontiers in Immunology.2022;[Epub]     CrossRef
DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
Ji Cheol Bae
Endocrinology and Metabolism.2022; 37(6): 858.     CrossRef
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Narjes Nasiri-Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, Ioannis Kyrou, Christos S. Mantzoros, Georgios Kyriakopoulos, Antonios Chatzigeorgiou, Vassiliki Kalotychou, Manpal S. Randeva, Kamaljit Chatha, Konstantinos Kontzoglou, Gregory Kaltsas, Athana
International Journal of Molecular Sciences.2021; 22(2): 818.     CrossRef
Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
Sook Jung Lee, Byung-Wan Lee
The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clinical and Molecular Hepatology.2021; 27(2): 257.     CrossRef
Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes: A Network Meta-Analysis
Jingxuan Lian, Jianfang Fu
Frontiers in Endocrinology.2021;[Epub]     CrossRef
Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives
Christina-Maria Flessa, Ioannis Kyrou, Narjes Nasiri-Ansari, Gregory Kaltsas, Athanasios G. Papavassiliou, Eva Kassi, Harpal S. Randeva
Current Obesity Reports.2021; 10(2): 134.     CrossRef
Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
Jingxuan Lian, Jianfang Fu
Frontiers in Endocrinology.2021;[Epub]     CrossRef
Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome
Stewart G. Albert, Emily M. Wood
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(5): 102232.     CrossRef
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
Martina Hüttl, Irena Markova, Denisa Miklankova, Iveta Zapletalova, Martin Poruba, Martin Haluzik, Ivana Vaněčkova, Hana Malinska
International Journal of Molecular Sciences.2021; 22(21): 11513.     CrossRef
Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
Yuting Ma, Chengxia Kan, Hongyan Qiu, Yongping Liu, Ningning Hou, Fang Han, Junfeng Shi, Xiaodong Sun
Frontiers in Pharmacology.2021;[Epub]     CrossRef
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
Dimitrios Patoulias, Michael Doumas
Clinical and Molecular Hepatology.2020; 26(4): 582.     CrossRef